The application for the Phase 3 clinical trial of Yunding Xinyao Sacituzumab Govitecan was approved

The application for a new drug clinical trial will be part of a global Phase 3 TROPiCS-04 clinical trial, and Yunding Xinyao plans to recruit patients for this Phase 3, Global Multi-Center, Open Label, Randomized Clinical Trial in China.
patients will be randomly assigned to the sacituzumab govitecan-hziy group or the doctor's choice of treatment (TPC) group, including yew alcohol, dositan and changchun fluine.
the clinical trial aims to evaluate sacituzumab govitecan-hziy with standard chemotherapy in patients with metastatic or locally advanced urethra skin cancer who are still progressing after treatment with platinum drug chemotherapy and PD-1/PD-L1 antibodies.
previous study of sacituzumab govitecan-hziy critical Phase 2 TROPHY U-01 in 113 mUC patients had positive results and was conducted in the European Essomatic 2 Published at the 2020 annual meeting, the results confirm earlier studies showing that sacituzumab govitecan-hziy is significantly active and safe in mUC patients treated with platinum drug chemotherapy and checkpoint inhibitors (CPI).
results showed that for multi-line mUC patients, sacituzumab govitecan-hziy achieved an overall remission rate (ORR) of 27% and a medium remission duration (DOR) of 5.9 months.
Sacituzumab govitecan-hziy, an allergy that has been approved by the U.S. Food and Drug Administration (FDA) as a fast track. "Based on the compelling and compelling data available, we believe that sacituzumab govitecan-hziy has the hope of providing new treatment options for patients with advanced urinary tract cortical cancer, which will improve the existing standards of treatment and care for the disease," said Seyang, chief medical officer of
Yunding Xinyao Oncology.
, urethra skin cancer is the most common type of histology of bladder cancer, and the incidence and mortality rates have been increasing year by year in recent years.
look forward to working with Chinese researchers and patients to make this trial a good one.
" Related to urethra cancer urethra epithelial cancer is a type of cancer that starts with urethra epithelial cells, which are located in the urethra and form the urinary system with the bladder, urethra, kidneys, and other organs.
2019, the number of cases of urethra cancer in China reached 764,000, according to Frost and Sullivan.
about Sacituzumab Govitecan-Hziy Sacituzumab govitecan-hziy is a similar first-of-its-kind antibody drug conjunctivity, targeting TRAP-2, a membrane antigen that is overexpressed in many common epithelial cancers.
under a licensing agreement with Gilead Sciences, YumDing Xinyao has exclusive interest in the development, registration and commercialization of sacituzumab govitecan-hziy in Greater China, South Korea and some Southeast Asian countries for all cancer adaptations.
: The original text has been deleted